This clinical trial, sponsored by Dr. Patricia Shi, investigates the safety and efficacy of administering Plerixafor 16 hours prior to apheresis in patients with Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM) undergoing autologous stem cell collection. The trial aims to optimize the timing of Plerixafor administration, which could enhance patient convenience and potentially improve stem cell yield. Given the increasing prevalence of NHL and MM, this study could have significant implications for the market, particularly for companies involved in hematopoietic stem cell mobilization. The collaboration with Genzyme, a Sanofi Company, suggests a strategic partnership that may enhance the asset's visibility and market reach. The results could influence clinical practice guidelines and provide a competitive edge in the stem cell mobilization space.